Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma

European Journal of Dermatology

Volumn 23, Issue 1, 2013, Pages 118-

  Degen, Annette ^a   Völker, Bernward ^b   Kapp, Alexander ^a   Gutzmer, Ralf ^a  

^a Skin Cancer Center Hannover   (Germany)

^b NORDSTADT HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DABRAFENIB; MOMETASONE FUROATE; VEMURAFENIB;

ADULT; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CAUCASIAN; COMPRESSION THERAPY; ERYTHEMA NODOSUM; FEMALE; HUMAN; HUMAN TISSUE; LETTER; LOW DRUG DOSE; LYMPH NODE DISSECTION; METASTATIC MELANOMA; PANNICULITIS; SENTINEL LYMPH NODE METASTASIS; SKIN BIOPSY; SUBCUTANEOUS NODULE;

ADULT; ANTINEOPLASTIC AGENTS; ERYTHEMA NODOSUM; FEMALE; HUMANS; INDOLES; LYMPHATIC METASTASIS; MELANOMA; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84875022015     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1915     Document Type: Letter

References (5)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
2. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-15.
3. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-21.
4. Zimmer L, Livingstone E, Hillen U, Doemkes S, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012; 148: 357-61.
5. Infante J, Falchook G, Lawrence D, et al. Phase 1/2 study to assess safety, pharmacokinetics, and, efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK 212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) [abstract 8503]. J Clin Oncol 2011; 29.(suppl).